Nordicus Partners Corp

Nordicus Partners Corp is a U.S.-listed business accelerator and holding company focused on Nordic life sciences ventures. It scouts early-stage biotechnology companies, provides strategic and operational support, and builds ownership positions in portfolio companies that are advancing drug and treatment candidates.

0.46

— Nordicus Partners Corp
%
Business acceleration35% Support services for early-stage life sciences companies, including milestone planning and operating guidance.
Strategic advisory20% Hands-on advice on management, governance, and company-building for portfolio firms.
Capital formation and ownership25% Equity-based investment and acquisition of portfolio companies.
Commercialization support20% Introductions to strategic partners and talent to help advance development programs.

Nordicus serves early-stage Nordic life sciences companies developing drugs or treatments for unmet medical needs...

  • Early-stage Nordic life sciences companiesprimary

    Companies developing drug or treatment candidates that need capital, governance, and milestone support.

  • Portfolio company management teamsprimary

    Founders and executives who receive operational advice, board support, and partner introductions.

  • Large pharmaceutical partnerssecondary

    Potential strategic partners that may license, invest in, or acquire programs after de-risking.

  • Public equity investorssecondary

    Investors buying Nordicus shares for exposure to a portfolio of early-stage biotech assets.

Nordicus sources opportunities in the Nordic region and supports companies as they pursue the U.S. market...

  • •Sourcing focus is the Nordic region
  • •Portfolio companies are supported for U.S. market entry
  • •Operations blend Nordic and U.S. teams
  • •Geography affects regulatory, clinical, and commercialization paths
  • •Cross-border structure supports acquisition and exit options

Nordicus’ strategy is to identify early-stage Nordic life sciences companies, accelerate them through key development...

01
Source and select high-potential Nordic life sciences companiesshort-term

Early access to differentiated assets is central to the accelerator model.

02
De-risk programs through milestone executionmedium-term

Clinical and regulatory progress increases valuation and exit optionality.

03
Monetize through acquisition or strategic exitmedium-term

Ownership and exit pathways are the main value-creation mechanism.

Nordicus is exposed to the binary risks of early-stage drug development, where clinical, regulatory, and financing...

critical

Clinical development failure

Portfolio value depends on drug candidates advancing through research and trials.

Scope
Preclinical and Phase I biotech assets
Materiality
high
high

Regulatory approval risk

Products cannot be commercialized without successful regulatory review.

Scope
Drug development programs
Materiality
high
high

Capital raising risk

The accelerator and holding-company model requires ongoing funding for portfolio support and acquisitions.

Scope
Corporate funding and portfolio financing
Materiality
high
high

Portfolio concentration

A small number of biotech holdings can drive most of the company’s value.

Scope
Orocidin A/S, Bio-Convert A/S and related holdings
Materiality
high
medium

Valuation and impairment risk

Intangible assets and acquired programs may require fair-value reassessment and impairment charges.

Scope
IPR&D and indefinite-lived intangible assets
Materiality
medium
Indefinite-lived intangible asset impairment
Can create large non-cash charges if fair value falls below carrying value
Fair value of financial instruments
Affects reported liabilities, equity, and earnings volatility
Business combination valuation
Determines goodwill/intangible balances and future impairment exposure
Foreign currency translation
Moves accumulated other comprehensive income and equity

PROVECTUS BIOPHARMACEUTICALS, INC.

PVCT · Pharmaceutical Preparations

Greenland Mines Ltd

GRML · Biological Products, (No Diagnostic Substances)

Nautilus Biotechnology, Inc.

NAUT · Laboratory Analytical Instruments

Liminatus Pharma, Inc.

LIMN · Biological Products, (No Diagnostic Substances)

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

: 29/04/2026